Luke Dreisbach

1.9k total citations
23 papers, 960 citations indexed

About

Luke Dreisbach is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luke Dreisbach has authored 23 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luke Dreisbach's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and Acute Myeloid Leukemia Research (3 papers). Luke Dreisbach is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and Acute Myeloid Leukemia Research (3 papers). Luke Dreisbach collaborates with scholars based in United States, Australia and United Kingdom. Luke Dreisbach's co-authors include Donald Woytowitz, Martin R. Weber, W. Heim, Thomas J. Lynch, Michael McCleod, Taral Patel, Eugene Paschold, Shaker R. Dakhil, Nicholas Iannotti and Robert C. Hermann and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Luke Dreisbach

21 papers receiving 937 citations

Peers

Countries citing papers authored by Luke Dreisbach

Since Specialization

Citations

This map shows the geographic impact of Luke Dreisbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke Dreisbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke Dreisbach more than expected).

Fields of papers citing papers by Luke Dreisbach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke Dreisbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke Dreisbach. The network helps show where Luke Dreisbach may publish in the future.

Co-authorship network of co-authors of Luke Dreisbach

This figure shows the co-authorship network connecting the top 25 collaborators of Luke Dreisbach. A scholar is included among the top collaborators of Luke Dreisbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke Dreisbach. Luke Dreisbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer. 2024 ·Journal of Clinical Oncology ·Nashat Gabrail, Miranda Gogishvili, Tamta Makharadze, (unknown), (unknown), (unknown), Emad Ibrahim, Daniel Brungs, Luke Dreisbach, (unknown), Solange Peters, Christopher Nguyen, (unknown), Siyu Li, (unknown), Israel Lowy, Matthew G. Fury, Luca Paoluzzi, Tamar Melkadze	2
2	A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%. 2024 ·Journal of Clinical Oncology ·(unknown), Tamar Melkadze, (unknown), Nashat Gabrail, (unknown), Emad Ibrahim, Luke Dreisbach, Daniel Brungs, (unknown), Miranda Gogishvili, Natalie I. Vokes, (unknown), Christopher Nguyen, (unknown), Siyu Li, Mark Salvati, Israel Lowy, Matthew G. Fury, Luca Paoluzzi	4
3	PROSTATE CANCER WITH ISOLATED LUNG METASTASIS: AN UNUSUAL PRESENTATION 2021 ·CHEST Journal ·(unknown), (unknown), (unknown), Luke Dreisbach, (unknown)	1
4	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial 2020 ·Nature Medicine ·Alain P. Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert, (unknown), Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. Messino, Dennis F. Moore, Christopher D. Lao, Bryan A. Faller, Rangaswamy Govindarajan, (unknown), Luke Dreisbach, James Moon, Kenneth F. Grossmann, Antoni Ribas	67
5	Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320. 2020 ·Journal of Clinical Oncology ·Alain P. Algazi, Megan Othus, Adil Daud, Janice M. Mehnert, Thach‐Giao Truong, Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. Messino, Dennis F. Moore, Christopher D. Lao, Bryan A. Faller, Rangaswamy Govindarajan, (unknown), Luke Dreisbach, James Moon, Kenneth F. Grossmann, Roger S. Lo, Antoni Ribas	0
6	Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma 2020 ·Cancer Research ·Alain P. Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert, Thach‐Giao Truong, Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. Messino, Dennis F. Moore, Christopher D. Lao, Bryan A. Faller, Rangaswamy Govindarajan, (unknown), Luke Dreisbach, James Moon, Kenneth Grossman, Antoni Ribas	4
7	Abstract A084: DENALI: a 3-arm double-blind randomized phase 2 study of carboplatin, pemetrexed, and placebo (CPP) versus carboplatin, pemetrexed, and either 1 or 2 truncated courses of demcizumab (CPD) in patients with non-squamous non-small cell lung cancer (NSCLC) 2018 ·Molecular Cancer Therapeutics ·Brett Hughes, Andrew Dean, Ben Markman, Luke Dreisbach, Mariano Provencio, Libero Ciuffreda, Rachel Dear, Peter R. Graze, (unknown), Baerin Houghton, Teresa Morán, Rachel Roberts, Grace K. Dy, Álvaro Taus, (unknown), Rainer K. Brachmann, Robert Stagg, Ramaswamy Govindan	3
8	TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer 2013 ·Cancer ·Charles S. Fuchs, Marwan Fakih, Lee S. Schwartzberg, Allen Lee Cohn, Lorrin Yee, Luke Dreisbach, Mark Kozloff, (unknown), Francesco Galimi, Yang Pan, Vincent Haddad, Cheng‐Pang Hsu, (unknown), Leonard B. Saltz	55
9	A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters 2011 ·Journal of Vascular and Interventional Radiology ·Cameron K. Tebbi, John J. Costanzi, Robert J. Shulman, Luke Dreisbach, Brian R. Jacobs, Martha Blaney, Mark Ashby, Barbara S. Gillespie, Susan M. Begelman	8
10	Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients With Advanced Solid Malignancies 2009 ·American Journal of Clinical Oncology ·Daruka Mahadevan, Luke Dreisbach, (unknown), (unknown), (unknown), S. Kurtin, Daniel D. Von Hoff	2
11	Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line advanced NSCLC: Analysis of the BMS099 trial 2009 ·Journal of Clinical Oncology ·Taral Patel, Luke Dreisbach, Michael McCleod, W. Heim, Robert C. Hermann, Donald Woytowitz, Haolan Lu, Martin R. Weber, Thomas J. Lynch	2
12	Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide. 2009 ·Blood ·Roger M. Lyons, Richard A. Larson, (unknown), Sunil Gandhi, Delong Liu, (unknown), Luke Dreisbach, (unknown), (unknown), Janet Franklin, Dietmar Berger	10
13	TROPICS 2: A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters. 2009 ·Blood ·Cameron K. Tebbi, John J. Costanzi, Robert J. Shulman, Luke Dreisbach, Brian R. Jacobs, Martha Blaney, Mark Ashby, Barbara S. Gillespie, Susan M. Begelman	1
14	B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Thomas J. Lynch, Taral Patel, Luke Dreisbach, Michael McCleod, W. Heim, (unknown), (unknown), (unknown), Martin R. Weber, Donald Woytowitz	70
15	A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naïve, unresectable pancreatic adenocarcinoma 2007 ·Journal of Clinical Oncology ·Hoa Khong, Luke Dreisbach, Hedy L. Kindler, David Trent, Krzysztof Jeziorski, (unknown), Tadeusz Popiela, (unknown), (unknown)	34
16	Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q 2007 ·Blood ·Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah A. Thomas, Robert Knight, M. Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List	308
17	A Durable Response to Relapsing Clostridium difficile Colitis May Require Combined Therapy with High-dose Oral Vancomycin and Intravenous Immune Globulin 2006 ·Infectious Diseases in Clinical Practice ·Lawrence A. Cone, Carlos López, (unknown), (unknown), (unknown), (unknown), Luke Dreisbach	6
18	Fatal Bacillus cereus endocarditis masquerading as an anthrax-like infection in a patient with acute lymphoblastic leukemia: case report. 2005 ·PubMed ·Lawrence A. Cone, Luke Dreisbach, (unknown), (unknown), (unknown)	22
19	Cellulitis and Septic Arthritis Caused by Campylobacter fetus and Campylobacter jejuni 2003 ·JCR Journal of Clinical Rheumatology ·Lawrence A. Cone, (unknown), Joel Hirschberg, (unknown), Luke Dreisbach, (unknown)	10
20	Campylobacter fetus subsp. fetus cellulitis and bacteremia in a patient with lymphoma: A case report and literature review 2000 ·Lawrence A. Cone, (unknown), (unknown), Luke Dreisbach	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact